PDE5-IN-13

• Description:

  PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active[1].

• UNSPSC:

  12352005

• Target:

  Phosphodiesterase (PDE)

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Smiles:

  C[C@@H](NC1=CC=CC(C(C2=CC=C(OC)C=C2)=C3C#N)=C1N(CC4=CC=CC=C4)C3=O)C5=CC=CC=N5

• Molecular Formula:

  C31H26N4O2

• Molecular Weight:

  486.56

• References & Citations:

  [1]Zhang B, et.al. Discovery and Optimization of Dihydroquinolin-2 (1H) -ones as Novel Highly Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. J Med Chem. 2024 Dec 26;67 (24) :22134-22144.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  PDE1; PDE10; PDE11; PDE2; PDE3; PDE4; PDE5; PDE6; PDE7; PDE8; PDE9